Lovastatin-induced E2F-1 modulation and its effect on prostate cancer cell death

Carcinogenesis

Volumn 22, Issue 10, 2001, Pages 1727-1731

  Park, Chaehwa ^a   Lee, Inkyoung ^a   Kang, Won Ki ^a  

^a Sungkyunkwan University School of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN A; CYCLIN B1; CYCLIN D1; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; MYC PROTEIN; PROTEASOME; PROTEIN P21; PROTEIN P27; TRANSCRIPTION FACTOR E2F;

APOPTOSIS; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CANCER INHIBITION; CELL CYCLE; CELL CYCLE S PHASE; CELL DEATH; CELL POPULATION; CONTROLLED STUDY; DOWN REGULATION; DRUG MECHANISM; DRUG RESPONSE; DRUG TARGETING; ENZYME DEGRADATION; GENE EXPRESSION; HUMAN; HUMAN CELL; MEDIATOR; MODULATION; ONCOGENE; ONCOGENE C MYC; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; TRANSCRIPTION REGULATION; TUMOR SUPPRESSOR GENE;

APOPTOSIS; CALPAIN; CELL CYCLE PROTEINS; CELL SURVIVAL; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLIN-DEPENDENT KINASE INHIBITOR P27; CYCLINS; CYSTEINE PROTEINASE INHIBITORS; DNA-BINDING PROTEINS; E2F TRANSCRIPTION FACTORS; E2F1 TRANSCRIPTION FACTOR; HUMANS; HYDROXYMETHYLGLUTARYL COA REDUCTASES; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LOVASTATIN; MALE; OLIGOPEPTIDES; PROSTATIC NEOPLASMS; RNA, MESSENGER; TRANSCRIPTION FACTORS; TRANSCRIPTION, GENETIC; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEINS;

EID: 0034789703     PISSN: 01433334     EISSN: None     Source Type: Journal    
DOI: 10.1093/carcin/22.10.1727     Document Type: Article

References (40)

1. Drug-induced apoptosis is not necessarily dependent on macromolecular synthesis or proliferation in the p53-negative human prostate cancer cell line PC-3
2. Inhibition of cholesterol synthesis with compactin renders growth of cultured cells dependent on the low density lipoprotein receptor
3. Mevinolin: A highly potent competitive inhibitor of hydroxymethylglutaryl-coenzyme A reductase and a cholesterol-lowering agent
4. 1 to multiple cell cycles by lovastatin
5. (+/-) mice
6. E2F and cell proliferation: A world turned upside down
7. Role for the p53 homologue p73 in E2F-1-induced apoptosis
8. Role of the p53-homologue p73 in E2F1-induced apoptosis
9. p73 function is inhibited by tumor-derived p53 mutants in mammalian cells
10. A common polymorphism acts as an intragenic modifier of mutant p53 behaviour
11. The regulation of E2F by pRB-family proteins
12. Cyclin A-kinase regulation of E2F-1 DNA binding function underlies suppression of an S-phase checkpoint
13. Expression of transcription factor E2F1 induces quiescent cells to enter S phase
14. Oncogenic capacity of the E2F1 gene
15. Differential responsiveness of human bronchial epithelial cells, lung carcinoma cells, and bronchial fibroblasts to interferon-γ in vitro
16. E2F1 messenger RNA is destabilized in response to a growth inhibitor in normal human keratinocytes, but not in a squamous carcinoma cell line
17. The retinoblastoma gene product protects E2F-1 from degradation by the ubiquitin-proteasome pathway
18. The molecular basis of E2F-1/DP-1-induced S-phase entry and apoptosis
19. Transcription of the E2F-1 gene is rendered cell cycle-dependent by E2F DNA-binding sites within its promoter
20. Regulation of E2F-1 gene expression by p130 (Rb2) and D-type cyclin kinase activity
21. WAFI/CIPI in human prostate carcinoma cells
22. Inhibition of E2F activity by the cyclin-dependent protein kinase inhibitor p21 in cells expressing or lacking a functional retinoblastoma protein
23. (WAFI/CIPI) gene
24. The ubiquitin-proteasome pathway is required for processing the NF-κB1 precursor protein and the activation of NF-κB
25. Inhibition of proteasome activities and subunit-specific amino-terminal threonine modification by lactacystin
26. waf1 leads to increased inhibition of E2F-1 phosphorylation and sensitivity to anticancer drugs in retinoblastoma-negative human sarcoma cells
27. Caspase-7 is activated during lovastatin-induced apoptosis of the prostate cancer cell line LNCaP
28. Potentiated antitumor effects of cisplatin and lovastatin against MmB16 melanoma in mice
29. Lovastatin and phenylacetate inhibit the induction of nitric oxide synthase and cytokines in rat primary astrocytes, microglia, and macrophages
30. Inhibition of E2F activity by the cyclin-dependent protein kinase inhibitor p21 in cells expressing or lacking a functional retinoblastoma protein
31. Transforming growth factor β induces the cyclin-dependent kinase inhibitor p21 through a p53-independent mechanism
32. Expression of the E2F1 transcription factor overcomes type β transforming growth factor-mediated growth suppression
33. 1/S-regulatory genes
34. 1 arrest in normal and tumor breast cells is through inhibition of CDK2 activity and redistribution of p21 and p27, independent of p53
35. Non-sterol compounds that regulate cholesterogenesis. Analogues of farnesyl pyrophosphate reduce 3-hydroxy-3-methylglutaryl-coenzyme A reductase levels
36. Regulation of the mevalonate pathway
37. Inhibition of cell growth by lovastatin is independent of ras function
38. Suppression of murine neuroblastoma growth in vivo by mevinolin, a competitive inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A reductase
39. Apoptosis: Mode of cell death induced in T cell leukemia lines by dexamethasone and other agents
40. Intracellular alkalinization suppresses lovastatin-induced apoptosis in HL-60 cells through the inactivation of a pH-dependent endonuclease